Pub Date : 2018-10-01DOI: 10.1097/01.op9.0000546434.86641.a4
{"title":"EXHIBITORS AND EXHIBITOR PROFILES","authors":"","doi":"10.1097/01.op9.0000546434.86641.a4","DOIUrl":"https://doi.org/10.1097/01.op9.0000546434.86641.a4","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43930901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-01DOI: 10.1097/OP9.0000000000000007
I. S. Hamid, E. B. Aksono, M. Sukmanadi, M. T. E. Purnama
Abstract This research has been conducted on the antiangiogenesis activity test of the tin leaf (Ficus carica L.) on the number of blood vessels and vascular endothelial growth factor (VEGF) expression of chorioallantoic membrane (CAM) of embryonated chicken eggs. The general objective of this study is the use of natural products from the F. carica L. as chemopreventive in cancer through the mechanism of inhibition of angiogenesis. Inhibition of angiogenesis, supply of nutrients and oxygen to cancer cells will also be inhibited, so that indirectly cancer cells will be stunted. This study used 25 embryonated chicken eggs that divided into 5 treatments and each treatment has 5 repetitions. This treatment includes placebo negative controls, celecoxib-positive controls, and 3 treatment groups were given a water extract of F. carica L. which was divided into several doses of 75, 90, and 110 &mgr;g. The result found a significant difference (P < .05) in the macroscopic observation of the number of blood vessels in the CAM loaded with the paper dish. Observation of VEGF expression in vascular endothelial cells in the CAM also had a significant difference (P < .05). The optimal dose of water extract of F. carica L. of 90 &mgr;g has been able to inhibit the formation of new blood vessels by 65.51% and reduce VEGF expression by 45% in the chorioallantoic membrane. Thus, it can be concluded that the administration of water extract of F. carica L. can inhibit the formation of new blood vessels and inhibit VEGF expression.
{"title":"Antiangiogenesis activity test of tin leaf (Ficus carica L.) on the number of blood vessels and VEGF expression of chorioallantoic membrane of embryonated chicken eggs","authors":"I. S. Hamid, E. B. Aksono, M. Sukmanadi, M. T. E. Purnama","doi":"10.1097/OP9.0000000000000007","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000007","url":null,"abstract":"Abstract This research has been conducted on the antiangiogenesis activity test of the tin leaf (Ficus carica L.) on the number of blood vessels and vascular endothelial growth factor (VEGF) expression of chorioallantoic membrane (CAM) of embryonated chicken eggs. The general objective of this study is the use of natural products from the F. carica L. as chemopreventive in cancer through the mechanism of inhibition of angiogenesis. Inhibition of angiogenesis, supply of nutrients and oxygen to cancer cells will also be inhibited, so that indirectly cancer cells will be stunted. This study used 25 embryonated chicken eggs that divided into 5 treatments and each treatment has 5 repetitions. This treatment includes placebo negative controls, celecoxib-positive controls, and 3 treatment groups were given a water extract of F. carica L. which was divided into several doses of 75, 90, and 110 &mgr;g. The result found a significant difference (P < .05) in the macroscopic observation of the number of blood vessels in the CAM loaded with the paper dish. Observation of VEGF expression in vascular endothelial cells in the CAM also had a significant difference (P < .05). The optimal dose of water extract of F. carica L. of 90 &mgr;g has been able to inhibit the formation of new blood vessels by 65.51% and reduce VEGF expression by 45% in the chorioallantoic membrane. Thus, it can be concluded that the administration of water extract of F. carica L. can inhibit the formation of new blood vessels and inhibit VEGF expression.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44658401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-01DOI: 10.1097/01.op9.0000546424.25653.be
{"title":"LETTER OF WELCOME","authors":"","doi":"10.1097/01.op9.0000546424.25653.be","DOIUrl":"https://doi.org/10.1097/01.op9.0000546424.25653.be","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49071310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-01DOI: 10.1097/op9.0000000000000008
{"title":"Proceedings Book for 4th ECOP (European Conference of Oncology Pharmacy) 25–27 October 2018, Nantes, France: Erratum","authors":"","doi":"10.1097/op9.0000000000000008","DOIUrl":"https://doi.org/10.1097/op9.0000000000000008","url":null,"abstract":"","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/op9.0000000000000008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43599056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-01DOI: 10.1097/OP9.0000000000000005
Yohannes A. Gessese, T. G. Fenta, Mathewos A. Weldegiorgis
Background: Chemotherapy errors affect several steps of medication-use process. A reduction of errors and toxicities, and an increase in error awareness, dose verification, proper documentation, and appropriateness of supportive care treatment are important. The present study was conducted to assess the medication-use process and dose-related errors in an outpatient adult oncology unit of Tikur Anbesa Specialized Hospital. Methods: An institutional-based cross-sectional study was conducted in an oncology outpatient adult oncology unit of Tikur Anbesa Specialized Hospital between May 1 and June 30, 2012. A total of 212 patient records for 583 chemotherapy administrations were reviewed during the study period. Results: The overall dose-related error rate was found to be 228 (39.1%). Specific rate of dose-related errors were (under dosing 58 (25.4%), overdosing 52 (22.8%), inaccurately reconstituted doses 106 (46.5%), and inappropriately adjusted doses 12 (5.3%). Dose labeling and documentation of appropriate time of administration for each chemotherapy preparation were not evident in the unit records. Only 3/14 dose verifications and 3 dose documentation processes were found. Supportive care treatment was not performed according to the recommended standards. Of the 23 equipment and supplies needed for chemotherapy preparation and administration, only 8 were available. Conclusions: The findings of our study indicate that the medication-use process in an outpatient adult oncology unit was below expected standards in 2012. The hospital and the school of pharmacy should give emphasis on the establishment of pharmacist run oncology pharmacy for chemotherapy preparation. Policies and guidelines for chemotherapy mixing and administration service and standardization of the process workflow should be developed.
{"title":"Assessment of medication use process in adult oncology unit of Tikur Anbesa Specialized Hospital: A cross-sectional study in Addis Ababa, Ethiopia","authors":"Yohannes A. Gessese, T. G. Fenta, Mathewos A. Weldegiorgis","doi":"10.1097/OP9.0000000000000005","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000005","url":null,"abstract":"Background: Chemotherapy errors affect several steps of medication-use process. A reduction of errors and toxicities, and an increase in error awareness, dose verification, proper documentation, and appropriateness of supportive care treatment are important. The present study was conducted to assess the medication-use process and dose-related errors in an outpatient adult oncology unit of Tikur Anbesa Specialized Hospital. Methods: An institutional-based cross-sectional study was conducted in an oncology outpatient adult oncology unit of Tikur Anbesa Specialized Hospital between May 1 and June 30, 2012. A total of 212 patient records for 583 chemotherapy administrations were reviewed during the study period. Results: The overall dose-related error rate was found to be 228 (39.1%). Specific rate of dose-related errors were (under dosing 58 (25.4%), overdosing 52 (22.8%), inaccurately reconstituted doses 106 (46.5%), and inappropriately adjusted doses 12 (5.3%). Dose labeling and documentation of appropriate time of administration for each chemotherapy preparation were not evident in the unit records. Only 3/14 dose verifications and 3 dose documentation processes were found. Supportive care treatment was not performed according to the recommended standards. Of the 23 equipment and supplies needed for chemotherapy preparation and administration, only 8 were available. Conclusions: The findings of our study indicate that the medication-use process in an outpatient adult oncology unit was below expected standards in 2012. The hospital and the school of pharmacy should give emphasis on the establishment of pharmacist run oncology pharmacy for chemotherapy preparation. Policies and guidelines for chemotherapy mixing and administration service and standardization of the process workflow should be developed.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48191924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-04-01DOI: 10.1097/OP9.0000000000000003
C. Streicher, Annick Daulange
Introduction: In this study we describe the implementation in a hospital setting of pharmacist consultations, by oncology pharmacists, as part of a multidisciplinary consultation program (MCP) established for patients before they start a new oral anticancer treatment. Methods: Pharmacist consultations consisted of 3 steps in the MCP. (1) The first one was the preparation of the medication assessment with the realization of an accurate patient medication list. (2) The second step was the pharmacist consultation with the patient. The oncology pharmacist assessed the ability of the patient to self-manage their therapy at home and gave information about the new drug. To prevent potential drug, herbs, and food interactions, individual medication plans were also performed. (3) Finally, the oncology pharmacist completed and sent the multidisciplinary report to the community pharmacists with a satisfaction survey. Results: Ninety patients, enrolled in the MCP, received pharmacist consultations. Oncology pharmacists reported that 24% (n = 22) of the patients were not able to take their medicine by themselves and that information for the home caregiver was needed. The realization of the best possible medication history highlighted drug interactions in 36% (n = 32) of patients and required, for 4 patients, discontinuation of 1 drug of their regular medicines. With the information delivered by oncology pharmacists, 83% of the community pharmacists contacted were able to better advise the patient at the time of the oral anticancer agent dispensing. Conclusions: The implementation of the MCP with pharmacist consultations allowed us to better support patients who start new oral anticancer treatment and shows us how crucial the expertise of oncology pharmacists is. They contribute to limit drug-related problems especially by identifying drug, herbs, and food interactions but also by identifying the patients unable to self-manage their therapy at home. The collaboration established with the community pharmacists allowed us to improve patient management by sharing information and knowledge.
{"title":"Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent: A descriptive study","authors":"C. Streicher, Annick Daulange","doi":"10.1097/OP9.0000000000000003","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000003","url":null,"abstract":"Introduction: In this study we describe the implementation in a hospital setting of pharmacist consultations, by oncology pharmacists, as part of a multidisciplinary consultation program (MCP) established for patients before they start a new oral anticancer treatment. Methods: Pharmacist consultations consisted of 3 steps in the MCP. (1) The first one was the preparation of the medication assessment with the realization of an accurate patient medication list. (2) The second step was the pharmacist consultation with the patient. The oncology pharmacist assessed the ability of the patient to self-manage their therapy at home and gave information about the new drug. To prevent potential drug, herbs, and food interactions, individual medication plans were also performed. (3) Finally, the oncology pharmacist completed and sent the multidisciplinary report to the community pharmacists with a satisfaction survey. Results: Ninety patients, enrolled in the MCP, received pharmacist consultations. Oncology pharmacists reported that 24% (n = 22) of the patients were not able to take their medicine by themselves and that information for the home caregiver was needed. The realization of the best possible medication history highlighted drug interactions in 36% (n = 32) of patients and required, for 4 patients, discontinuation of 1 drug of their regular medicines. With the information delivered by oncology pharmacists, 83% of the community pharmacists contacted were able to better advise the patient at the time of the oral anticancer agent dispensing. Conclusions: The implementation of the MCP with pharmacist consultations allowed us to better support patients who start new oral anticancer treatment and shows us how crucial the expertise of oncology pharmacists is. They contribute to limit drug-related problems especially by identifying drug, herbs, and food interactions but also by identifying the patients unable to self-manage their therapy at home. The collaboration established with the community pharmacists allowed us to improve patient management by sharing information and knowledge.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47160355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.1097/OP9.0000000000000002
Michal Budinský, S. Kozáková
Background: The purpose of our study is to evaluate the effect of instrumental methods in radiopharmacy on radiation exposure of the staff preparing radiopharmaceuticals. Methods: Instrumental methods in radiopharmacy are used since 2004 as a tool of radiation protection optimization for the pharmacists after positron-emission tomography (PET) introduction to the department of nuclear medicine of Masaryk Memorial Cancer Institute (MMCI) in 2003. During 14 years of providing PET radiopharmaceuticals, different equipment and processes were used—DDS-A, &mgr;DDS-A and KARl100 (all Tema Sinergie). The increase in a number of instrumental equipment—2 &mgr;DDS-A and 1 KARl100, allows preparing 3 different radiopharmaceutical for PET (either [18F]FDG, [18F]FLT, [18F]NaF, [18F]choline, [18F]Vizamyl, [18C]methionine) in 1 day. The radiation exposure to the radiopharmacists was evaluated from ring dosimeters. Results: The introduction of PET in 2003 led to rise of the radiation dose over legislation limits to the radiopharmacists with personal maximum of 814.4 mSv/y for hands. As a tool of optimization, instrumental preparing radiopharmaceuticals for PET using DDS-A was introduced. In 2004, rapid reduction of radiation dose was recorded to personal maximum of 106.97 mSv/y for hands. The increase of number and types of PET radiopharmaceuticals used during 1 day required upgrade of equipment used and increase in its number. In 2009, former DDS-A was replaced by 2 &mgr;DDS-A. Another tool, KARl100 was installed in 2016. This led to further significant reduction of radiation dose to personal maximum of 24.91 mSv/y for hands. Conclusions: Introduction of PET and the need to prepare several different types of radiopharmaceutical lead to rise of radiation exposure and received dose of radiopharmacists. Introduction of instrumental methods in radiopharmacy is a tool for radiation protection optimization. In conclusion, it is the possible to state that instrumental methods in radiopharmacy have a significant effect on radiation protection of the radiopharmacists.
背景:本研究的目的是评价放射药学仪器方法对制备放射性药物工作人员辐射暴露的影响。方法:自2003年Masaryk Memorial Cancer Institute (MMCI)核医学科引进正电子发射断层扫描(PET)后，2004年开始使用放射药学仪器方法作为优化药师放射防护的工具。在提供PET放射性药物的14年中，使用了不同的设备和工艺- DDS-A， &mgr;DDS-A和KARl100(均为Tema Sinergie)。仪器设备数量的增加- 2 &mgr;DDS-A和1 KARl100，允许在1天内制备3种不同的PET放射性药物([18F]FDG， [18F]FLT， [18F]NaF， [18F]胆碱，[18F]维扎美尔，[18C]蛋氨酸)。用环形剂量计对放射药理学家的辐射暴露进行了评估。结果:2003年引入PET后，放射药师的手部辐射剂量超过了立法限值，个人最高剂量为814.4 mSv/y。作为优化的工具，介绍了用DDS-A制备PET用放射性药物的方法。2004年，辐射剂量迅速减少，手部的个人最高剂量为106.97毫西弗/年。在1天内使用的PET放射性药物的数量和类型的增加需要升级所使用的设备并增加其数量。2009年，原DDS-A被2 &mgr;DDS-A所取代。另一个工具KARl100于2016年安装。这导致辐射剂量进一步显著减少，手部的个人最高辐射剂量为24.91毫西弗/年。结论:PET的引入和制备几种不同类型的放射性药物的需要导致放射药理学家的辐射暴露和接受剂量的增加。放射药学仪器方法的介绍是优化辐射防护的工具。总之，可以这样说，放射药学中的仪器方法对放射药理学家的辐射防护有显著的影响。
{"title":"Experience with instrumental methods in radiopharmacy as a tool of radiation protection optimization","authors":"Michal Budinský, S. Kozáková","doi":"10.1097/OP9.0000000000000002","DOIUrl":"https://doi.org/10.1097/OP9.0000000000000002","url":null,"abstract":"Background: The purpose of our study is to evaluate the effect of instrumental methods in radiopharmacy on radiation exposure of the staff preparing radiopharmaceuticals. Methods: Instrumental methods in radiopharmacy are used since 2004 as a tool of radiation protection optimization for the pharmacists after positron-emission tomography (PET) introduction to the department of nuclear medicine of Masaryk Memorial Cancer Institute (MMCI) in 2003. During 14 years of providing PET radiopharmaceuticals, different equipment and processes were used—DDS-A, &mgr;DDS-A and KARl100 (all Tema Sinergie). The increase in a number of instrumental equipment—2 &mgr;DDS-A and 1 KARl100, allows preparing 3 different radiopharmaceutical for PET (either [18F]FDG, [18F]FLT, [18F]NaF, [18F]choline, [18F]Vizamyl, [18C]methionine) in 1 day. The radiation exposure to the radiopharmacists was evaluated from ring dosimeters. Results: The introduction of PET in 2003 led to rise of the radiation dose over legislation limits to the radiopharmacists with personal maximum of 814.4 mSv/y for hands. As a tool of optimization, instrumental preparing radiopharmaceuticals for PET using DDS-A was introduced. In 2004, rapid reduction of radiation dose was recorded to personal maximum of 106.97 mSv/y for hands. The increase of number and types of PET radiopharmaceuticals used during 1 day required upgrade of equipment used and increase in its number. In 2009, former DDS-A was replaced by 2 &mgr;DDS-A. Another tool, KARl100 was installed in 2016. This led to further significant reduction of radiation dose to personal maximum of 24.91 mSv/y for hands. Conclusions: Introduction of PET and the need to prepare several different types of radiopharmaceutical lead to rise of radiation exposure and received dose of radiopharmacists. Introduction of instrumental methods in radiopharmacy is a tool for radiation protection optimization. In conclusion, it is the possible to state that instrumental methods in radiopharmacy have a significant effect on radiation protection of the radiopharmacists.","PeriodicalId":39134,"journal":{"name":"European Journal of Oncology Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/OP9.0000000000000002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61743698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：